← Surfer · Coach hub

Coach — Metabolic Hypothesis of Diabetes

Type 2 diabetes is usually managed as a numbers problem: fasting glucose, spikes, HbA1c, and a drug that moves the number. The working hypothesis here starts one layer upstream, with mitochondria that cannot turn available fuel into energy fast enough, and with high sugar and high insulin as the body's attempts to cope.

Safety first

The extended report opens with its cautions: "Do not change insulin or other glucose-lowering drugs from this page. Low blood sugar and ketoacidosis are emergencies. Prolonged fasting, major dietary shifts, or intensive metabolic protocols carry real risks and must be undertaken only under qualified medical supervision with appropriate monitoring." It is fair to the medicines too: "GLP-1 receptor agonists, SGLT2 inhibitors, insulin, and other pharmacotherapies have documented benefits in specific contexts and are not dismissed here; they are critiqued for what they leave unaddressed when used as primary long-term strategies without concurrent engine repair."

In practice, some situations always come before any idea in this essay: symptoms of low blood sugar, signs of ketoacidosis or a severe high-sugar state, infection, chest pain, pregnancy, and any question about type 1 diabetes. Cutting carbohydrates sharply or fasting while taking insulin, a sulfonylurea, or an SGLT2 inhibitor can cause dangerous lows or a form of ketoacidosis that can occur even at normal glucose levels, and it belongs with the physician who manages those risks. Eye and kidney screening keep their schedules. Nothing here promises a cure or freedom from medication.

Readouts and the engine

In the dominant approach, type 2 diabetes is defined and managed by its most visible readouts: fasting glucose, spikes after meals, HbA1c, and the high insulin and insulin resistance that travel with them. Treatments target those readouts. They suppress glucose output from the liver, increase insulin release or sensitivity, push glucose out through the urine, or supply insulin directly. These tools lower measured glucose, reduce some small-vessel complications in trials, and lower cardiovascular risk in selected people. The report's concern is what they can leave untouched: weight trajectories that do not restore metabolic flexibility, beta cells that keep working harder, digestive effects, the risk of low blood sugar, and patients who feel their disease is being managed rather than resolved.

Fuel everywhere, energy nowhere

The report borrows its central image from Coleridge's ancient mariner: "Water, water, everywhere, / Nor any drop to drink." In type 2 diabetes, glucose circulates in abundance and fat is stored in abundance, yet the mitochondria in muscle, liver, the insulin-producing beta cells, and the lining of blood vessels experience relative energy starvation.

The mechanism the report proposes is sequestration. Insulin resistance, a tolerance at the receptor level, limits how efficiently cells take up glucose, so the main carbohydrate fuel stays trapped in the blood. At the same time, high insulin suppresses the release of fat from fat cells, so the other great fuel stays locked in storage instead of reaching mitochondria for burning. The engine is starved not because fuel is absent, but because the hormonal response to the original energy shortfall keeps fuel away from the place it is needed. The more the system compensates, the less fuel reaches the struggling mitochondria, and the wider the gap becomes.

In this reading, high blood sugar is not the primary disease but a downstream signal and compensation. High insulin is compensatory as well: early on it forces storage past resistance, and later it reflects the heavy energy cost of making and secreting so much insulin from beta cells whose own mitochondria are compromised. The familiar vicious cycles of sugar toxicity and fat toxicity are real, but in the report's account they are amplifiers that accelerate damage to an already compromised engine, not the origin.

The primary lesion

The report places the core problem in mitochondrial ATP production. Mitochondria are not only energy factories; they are where fuel is turned into the cell's energy currency, where the balance of oxidation and reduction is managed, and where much of the cell's quality control and adaptive capacity lives. In the proposed model, the starting and sustaining lesion in most type 2 diabetes is impaired fuel oxidation in muscle, liver, beta cells, blood vessels, and other high-demand tissues. That can come from a less efficient or less capable energy chain, a sluggish gateway enzyme between sugar breakdown and the mitochondria, disordered fusion and division of mitochondria, suppressed building of new ones, and inflammatory and oxidative damage to their membranes. The result is a cell that can take up glucose, or have it forced upon it, but cannot burn it cleanly and completely. It starves in the midst of plenty.

The same shortfall appears differently in each tissue: insulin resistance in muscle, inappropriate glucose output from the liver, exhaustion of beta cells, and damage to small blood vessels. Diabetic retinopathy fits the pattern. In the conventional account it is sugar destroying capillaries, and sugar matters. But the retina is one of the most metabolically active tissues in the body. Loss of the supporting cells around capillaries, capillary dropout, swelling, and later abnormal new vessels can be read as the record of cells that could not maintain their barriers and flow, followed by a compensatory attempt to restore delivery. Injections that block the growth signal for new vessels treat a downstream step; they do not by themselves explain why the retina asked for vessels. The report is clear that this reading does not authorize skipping eye care or glucose emergency care.

Where the shortfall comes from

The report names four converging inputs, all forms of mismatch between human physiology and the modern environment. The first is a chronic load of refined carbohydrate combined with too little fermented, fiber-rich food, which keeps pressure on a marginal engine while starving gut bacteria of the material they turn into short-chain fatty acids that support mitochondrial health. The second is circadian disruption: artificial light after sunset, irregular eating windows, and broken sleep, which erase the daily rhythms of repair and renewal mitochondria depend on. The third is too little strength work and movement, which removes the main stimulus for building new mitochondria and maintaining reserve in muscle. The fourth is the cumulative effect of industrial seed oils, whose easily oxidized fats are built into mitochondrial membranes, along with ultra-processed food additives and reduced ancestral movement. Under those conditions the engine is asked to process a continuous, high-glycemic fuel mix without the fasting intervals, fermentable fibers, or mechanical loading that once allowed repair. Genetic and developmental vulnerability still matter; in this framing they set susceptibility to an environment that steadily erodes mitochondrial integrity.

The GLP-1 moment

The related diabesity hypothesis sharpens the point about the newest drugs. Incretin drugs can deliver large improvements in weight and HbA1c. Lean mass often falls with the waist; appetite is overridden rather than the engine restored; and weight often returns when the drug stops. The report calls that a canary, not proof that the mitochondrial lesion was repaired. That is a statement about what the numbers measure, not a case against the drugs. The essay on obesity follows the same engine through fat storage and fat loss.

Restoring the engine

The strategies that follow from this hypothesis are the same ones the site applies elsewhere. In the report's account, they mean prioritizing animal proteins and fats, including fermented vegetables such as sauerkraut and kimchi to feed gut bacteria, restricting refined carbohydrates, and avoiding industrial seed oils. They mean morning light, dim evenings, and consistent sleep. And they mean progressive resistance training with steady aerobic work, the main signals for building new mitochondria and restoring insulin sensitivity. The report adds that medically supervised prolonged fasting can enable deep cellular cleanup, and that NAD+ precursors, PQQ, CoQ10, and AMPK activators can serve as targeted adjuncts. It then draws the line itself: "None of this is a self-start protocol. Insulin, SGLT2 inhibitors, GLP-1 agonists, and other agents keep their place in acute and refractory settings."

Measures of capacity belong beside the glucose readings: grip strength, cardiorespiratory fitness, lean-mass trend, recovery after effort, sleep regularity, and continuous glucose patterns where a physician already uses them. The common measures of capacity and the endocrinology measures are described elsewhere, along with the shared failure modes, such as treating one drug as the whole strategy. A better HbA1c with collapsing fitness and sleep is an incomplete win if the engine was never addressed. The reverse error is just as real: ignoring the numbers in a crisis.

Limits

This is a working hypothesis, not a trial verdict that mitochondria-first strategies outperform guideline diabetes care on their own. It does not deny glucose toxicity, the microvascular benefits of glucose control, or the value of insulin, GLP-1 drugs, SGLT2 inhibitors, metformin, and related agents when they are indicated. It does not claim that unsupervised fasting, extreme carbohydrate elimination, or supplements reverse diabetes. And it does not treat type 1 diabetes as the same disease: type 1 is autoimmune loss of beta cells, with its own clocks and its own care.

The water is still everywhere. The task, in this hypothesis, is to repair the capacity to drink, with the physicians who manage the medicines kept in charge of every change. For the full argument, read the extended report on diabetes. The short version is in the lessons. Talk with your own physician before changing medications or supplements.

A working hypothesis, open to correction and revised as new evidence arrives. Last revised October 17, 2026.

See the notice at the top of this page. Working hypothesis, not medical advice. Individual care requires personalized evaluation by a qualified physician.